ArticleFrontiers in microbiology2025
Exploring the antibacterial potential of arthrocolins against extensively drug-resistant
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cloxiquine exerts bactericidal activity against Enterococcus faecalis through disruption of proton motive force and induction of reactive oxygen species.BMC microbiology · 2026Article
- Tibetan Medicine Liuwei Dingxiang Pills Decoction InhibitsInfection and drug resistance · 2026Article
- High-dose aztreonam potentiates the combined antimicrobial activity of ceftazidime-avibactam against extensively drug-resistant New Delhi metallo-β-lactamase positiveFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) poses a serious clinical threat due to its intrinsic resistance mechanisms and the lack of effective therapeutic agents. This study aimed to evaluate the antibacterial activity of arthrocolins (Acs), a novel group of xanthene-like compounds isolated from Escherichia coli, against XDR-PA. Methods: Clinical data analysis was conducted to identify significant risk factors for XDR-PA infection. Drug susceptibility testing was performed to assess the effectiveness of Acs. Transmission electron microscopy (TEM) was used to observe cellular changes in Acs-treated bacteria, while integrated transcriptomic and metabolomic analyses were employed to investigate the underlying mechanisms. Results: Acs demonstrated significant antibacterial activity, inhibiting XDR-PA growth at low micromolar concentrations. The IC50 value was determined to be 3.094 μM. Clinical data analysis identified prolonged antimicrobial therapy, invasive procedures, and extended hospitalization as significant risk factors for XDR-PA infection. TEM revealed cell wall disruption and cytoplasmic condensation in Acs-treated bacteria. Integrated omics analyses indicated that Acs interferes with amino acid metabolism, impairing energy production and causing abnormal lipid accumulation. Discussion: These findings suggest that Acs exerts potent antibacterial effects through disruption of metabolic homeostasis and structural integrity. The study highlights the potential of Acs as a promising candidate for the treatment of XDR-PA infections, offering a new avenue for therapeutic development. The bacterial names cannot be italicized in the annotations. The revised abstract has been uploaded separately as an attachment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.